مقایسهٔ روش‌ها

	باندیت چند-بازویی (UCB، نمونه‌گیری تامپسون)	آزمایش تصادفی کنترل‌شده (RCT)	طراحی کارآزمایی‌های ترتیبی / گروهی ترتیبی
حوزه	طراحی آزمایش	طراحی آزمایش	طراحی آزمایش
خانواده	Hypothesis test	Hypothesis test	Hypothesis test
سال پیدایش	1952	1948	1979
پدیدآور	Robbins (1952); UCB1 by Auer et al. (2002); Thompson sampling by Thompson (1933)	James Lind (early precursor, 1747); modern formulation: Austin Bradford Hill & Medical Research Council (1948)	O'Brien & Fleming; Pocock; Lan & DeMets
نوع	Sequential decision / bandit algorithm	Interventional comparative study	Adaptive stopping trial design
منبع بنیادین	Auer, P., Cesa-Bianchi, N., & Fischer, P. (2002). Finite-Time Analysis of the Multiarmed Bandit Problem. Machine Learning, 47(2–3), 235–256.	Schulz, K.F., Altman, D.G., Moher, D., for the CONSORT Group (2010). CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. BMJ, 340, c332.	O'Brien, P.C. & Fleming, T.R. (1979). A Multiple Testing Procedure for Clinical Trials. Biometrics, 35(3), 549–556.
نام‌های دیگر	MAB, bandit algorithm, UCB1, Thompson sampling	RCT, randomised controlled trial, clinical trial, Randomize Kontrollü Çalışma (RCT) Tasarımı	group sequential design, adaptive stopping design, Ardışık Deneme Tasarımı (Sequential / Group Sequential)
مرتبط	4	7	3
خلاصه	The multi-armed bandit (MAB) is an adaptive experimental framework that allocates trials sequentially across competing arms to minimise cumulative regret while simultaneously learning which arm performs best. Formalised by Robbins in 1952 and given finite-time guarantees by Auer et al. (2002), it balances exploration of uncertain options against exploitation of currently known best options — outperforming classical A/B testing whenever early stopping or cost-sensitive allocation matters.	A randomized controlled trial (RCT) is the gold standard experimental design in clinical and health research, in which participants are randomly allocated to a treatment group or a control group so that the effect of an intervention can be measured with the highest possible degree of internal validity. The modern parallel-group RCT was formalized by Austin Bradford Hill and the Medical Research Council in their landmark streptomycin trial of 1948, and its reporting is governed today by the CONSORT 2010 guidelines (Schulz et al., 2010).	Sequential and group sequential trial designs allow a study to be stopped early — or continued — based on interim analyses conducted as data accumulate. The core framework was formalised by O'Brien and Fleming in 1979 and extended by Lan and DeMets's alpha-spending approach, and it controls the overall Type I error rate across all planned looks by pre-specifying both efficacy and futility boundaries before enrolment begins.